IASLC World Conference on Lung Cancer

Neoadjuvant Triplet Regimen Safe, Effective in Patients With Resectable Mesothelioma

September 14, 2021

Updates from the ongoing S1619 trial suggest that a triplet combination regimen of neoadjuvant cisplatin, pemetrexed, and atezolizumab is effective and tolerable in the treatment of patients with resectable pleural mesothelioma.